Show simple item record

dc.contributor.author
Singer, Franziska
dc.contributor.author
Irmisch, Anja
dc.contributor.author
Toussaint, Nora C.
dc.contributor.author
Grob, Linda
dc.contributor.author
Singer, Jochen
dc.contributor.author
Thurnherr, Thomas
dc.contributor.author
Beerenwinkel, Niko
dc.contributor.author
Levesque, Mitchell P.
dc.contributor.author
Dummer, Reinhard
dc.contributor.author
Quagliata, Luca
dc.contributor.author
Rothschild, Sacha I.
dc.contributor.author
Wicki, Andreas
dc.contributor.author
Beisel, Christian
dc.contributor.author
Stekhoven, Daniel J.
dc.date.accessioned
2018-11-27T14:08:17Z
dc.date.available
2018-11-09T05:50:27Z
dc.date.available
2018-11-27T14:08:17Z
dc.date.issued
2018
dc.identifier.issn
1472-6947
dc.identifier.other
10.1186/s12911-018-0680-0
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/302453
dc.identifier.doi
10.3929/ethz-b-000302453
dc.description.abstract
Background Molecular precision oncology is an emerging practice to improve cancer therapy by decreasing the risk of choosing treatments that lack efficacy or cause adverse events. However, the challenges of integrating molecular profiling into routine clinical care are manifold. From a computational perspective these include the importance of a short analysis turnaround time, the interpretation of complex drug-gene and gene-gene interactions, and the necessity of standardized high-quality workflows. In addition, difficulties faced when integrating molecular diagnostics into clinical practice are ethical concerns, legal requirements, and limited availability of treatment options beyond standard of care as well as the overall lack of awareness of their existence. Methods To the best of our knowledge, we are the first group in Switzerland that established a workflow for personalized diagnostics based on comprehensive high-throughput sequencing of tumors at the clinic. Our workflow, named SwissMTB (Swiss Molecular Tumor Board), links genetic tumor alterations and gene expression to therapeutic options and clinical trial opportunities. The resulting treatment recommendations are summarized in a clinical report and discussed in a molecular tumor board at the clinic to support therapy decisions. Results Here we present results from an observational pilot study including 22 late-stage cancer patients. In this study we were able to identify actionable variants and corresponding therapies for 19 patients. Half of the patients were analyzed retrospectively. In two patients we identified resistance-associated variants explaining lack of therapy response. For five out of eleven patients analyzed before treatment the SwissMTB diagnostic influenced treatment decision. Conclusions SwissMTB enables the analysis and clinical interpretation of large numbers of potentially actionable molecular targets. Thus, our workflow paves the way towards a more frequent use of comprehensive molecular diagnostics in Swiss hospitals.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
BioMed Central
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Molecular diagnostics
en_US
dc.subject
NGS
en_US
dc.subject
Personalized medicine
en_US
dc.subject
Cancer diagnostic
en_US
dc.subject
Molecular tumor board
en_US
dc.title
SwissMTB: Establishing comprehensive molecular cancer diagnostics in Swiss clinics
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2018-10-29
ethz.journal.title
BMC Medical Informatics and Decision Making
ethz.journal.volume
18
en_US
ethz.journal.issue
1
en_US
ethz.journal.abbreviated
BMC med. inform. decis. mak.
ethz.pages.start
89
en_US
ethz.size
18 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
London
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02060 - Dep. Biosysteme / Dep. of Biosystems Science and Eng.::03790 - Beerenwinkel, Niko / Beerenwinkel, Niko
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02060 - Dep. Biosysteme / Dep. of Biosystems Science and Eng.::03790 - Beerenwinkel, Niko / Beerenwinkel, Niko
ethz.date.deposited
2018-11-09T05:50:28Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2018-11-27T14:08:24Z
ethz.rosetta.lastUpdated
2019-02-03T11:48:14Z
ethz.rosetta.exportRequired
true
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=SwissMTB:%20Establishing%20comprehensive%20molecular%20cancer%20diagnostics%20in%20Swiss%20clinics&rft.jtitle=BMC%20Medical%20Informatics%20and%20Decision%20Making&rft.date=2018&rft.volume=18&rft.issue=1&rft.spage=89&rft.issn=1472-6947&rft.au=Singer,%20Franziska&Irmisch,%20Anja&Toussaint,%20Nora%20C.&Grob,%20Linda&Singer,%20Jochen&rft.genre=article&
 Search via SFX

Files in this item

Thumbnail

Publication type

Show simple item record